Last reviewed · How we verify

vasopressin - early initiation

The Cleveland Clinic · FDA-approved active Small molecule

Vasopressin is a naturally occurring hormone that binds to vasopressin receptors to increase blood pressure and vasoconstriction, used in early septic shock management to restore hemodynamic stability.

Vasopressin is a naturally occurring hormone that binds to vasopressin receptors to increase blood pressure and vasoconstriction, used in early septic shock management to restore hemodynamic stability. Used for Septic shock (early initiation for hemodynamic support), Variceal bleeding.

At a glance

Generic namevasopressin - early initiation
Also known asvasopressin
SponsorThe Cleveland Clinic
Drug classVasopressor agent
TargetVasopressin receptor (V1 and V2)
ModalitySmall molecule
Therapeutic areaCritical Care / Sepsis
PhaseFDA-approved

Mechanism of action

Vasopressin acts as a potent vasoconstrictor by activating V1 receptors on vascular smooth muscle cells, leading to increased systemic vascular resistance and blood pressure. Early initiation in septic shock aims to rapidly restore perfusion pressure and reduce the need for catecholamine vasopressors. The hormone also has antidiuretic effects through V2 receptor activation in the kidney, helping maintain fluid balance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: